Lilly's retatrutide beats Ozempic on sugar and weight — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly said this morning that its investigational drug retatrutide was more effective than Novo Nordisk's Ozempic at lowering blood sugar in a large diabetes study.
- Retatrutide was also more effective than Ozempic at cutting weight in that same large diabetes study, giving Lilly the head-to-head win on two measures.
Why it matters: For Lilly, the head-to-head result puts its investigational retatrutide ahead of Novo Nordisk's marketed Ozempic on both blood sugar and weight in a large diabetes study. The contrast favors Lilly, and it does so with a drug that is still investigational rather than approved.
Ask SkimNews
